Assistive Communication Pioneer Poised for Double
Idea source: Origo, Per Johansson
Dynavox Group AB is the global leader in assistive communication technology for people with disabilities, offering hardware, software, and support services in over 65 countries.
Ticker: DYVOX | Timeframe: 12m | 📈 Bullish
Dynavox leads the assistive communication technology market with unique solutions for people with disabilities such as cerebral palsy, ALS, and autism. Despite strong fundamentals and proven societal value, the market underappreciates Dynavox’s growth potential, particularly in the underpenetrated U.S. market. With tariff protection, a scalable business model, and an expanding market share, Johansson forecasts a 100% upside potential within 12 months based on a 25x earnings multiple.
Setup: Market leader in the critically underserved assistive technology space, with ~50M people globally unable to communicate effectively without assistance, yet only ~2% are currently being helped.
Latest development: Recent acquisition of Link Assistive strengthens direct presence in Australia/New Zealand markets, following successful expansion strategy in Ireland and Denmark.
Reason for mispricing: Market underappreciates both the societal value and business model scalability; recent rebranding from Tobii Dynavox to Dynavox Group in 2024 may have created confusion.
Timing: Accelerating revenue growth with Q1 2025 showing 36% YoY increase; positive momentum from recent acquisitions and product developments.
Value catalysts: A growing elderly population is driving the adoption of assistive tech; expanding the global footprint through strategic distributor acquisitions; and medical device tariff exemptions provide margin protection.
Valuation: Currently trading at ~76x TTM P/E vs Johansson’s target of 25x forward earnings, implying significant upside as earnings growth accelerates.
Upside potential: 100% over the next 12 months, according to Johansson, supported by strong Q1 2025 results showing 34% currency-adjusted growth.
Risks: High current valuation requires continued strong execution; competition from other communication technologies; potential margin pressure if medical device tariff exemptions change.
Disclaimer - Not Investment Advice
The content on Lind Research is for informational purposes only and should not be considered as investment advice financial advice. One should always consult a qualified professional before making any investment decisions. Investments carry risks, including the potential loss of capital. Lind Research and its authors bear no liability for decisions made based on the information provided here. All views are personal and not reflective of any company mentioned. Lind Research, it’s affilaites, personnel, clients and/or partners might hold investments in securites discussed.
By accessing Lind Research, you acknowledge and agree to this disclaimer.